Q.U.A.R.O.N.A. [Prod.Tpex]
from the album Petali Di Loto
![](https://i1.rgstatic.net/ii/profile.image/532245796851712-1503908694544_Q64/Kai-Shi-6.jpg)
PDF) cGAS-STING pathway in cancer biotherapy
![](https://i1.rgstatic.net/ii/profile.image/11431281084372454-1663148232060_Q64/Li-Tianle-3.jpg)
PDF) cGAS-STING pathway in cancer biotherapy
![](https://i1.rgstatic.net/ii/profile.image/11431281202567572-1698926985790_Q64/Guo-Song-Liu-2.jpg)
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy
![](https://f4.bcbits.com/img/a0417081923_10.jpg)
Q.U.A.R.O.N.A. [Prod.Tpex]
![](https://i1.rgstatic.net/ii/profile.image/11431281109344226-1671887644682_Q64/Christian-Klein-3.jpg)
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy
![](https://journals.asm.org/cms/10.1128/jvi.00225-23/asset/7e6338e5-428c-4d80-a239-b38bf9fa4e3a/assets/images/large/jvi.00225-23-f001.jpg)
Cell-Intrinsic CD38 Expression Sustains Exhausted CD8+ T Cells by Regulating Their Survival and Metabolism during Chronic Viral Infection
![](https://i1.rgstatic.net/ii/profile.image/273589345714202-1442240192056_Q64/Andrea-Iaboni.jpg)
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy
![](https://i1.rgstatic.net/ii/profile.image/968871221686273-1608008308336_Q64/Gihoon-You.jpg)
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy
![](https://i1.rgstatic.net/ii/profile.image/1012121051598856-1618319871767_Q64/Jeffrey-Lee-38.jpg)
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy
![](https://i1.rgstatic.net/ii/profile.image/11431281196912179-1696866704229_Q64/Qiwei-Wang-16.jpg)
PDF) cGAS-STING pathway in cancer biotherapy
![](https://i1.rgstatic.net/ii/profile.image/11431281148942052-1681756654468_Q64/Enfu-Hui.jpg)
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy
![](https://c5.rgstatic.net/m/4671872220764/images/template/default/profile/profile_default_m.jpg)
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy